Methods for determining responsiveness to MEK/ERK inhibitors
US10501805B2 · kind B2 · utility
0Cited by
10References
15Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 3, 2015 |
| Grant date | Dec 10, 2019 |
| Priority date | — |
| Expiry date | May 29, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Q2600/156
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
A method for predicting the responsiveness of a cancer cell to an MEK inhibitor, comprising detecting the presence of at least one mutation in one or more genes selected from the group consisting of ADAM12, COL14A1, TNN, and TP53, in the cancer cell, by contacting a nucleic acid sample derived from the cancer cell with at least one oligonucleotide which allows specific detection of the mutation; wherein presence of mutation in ADAM12, COL14A1, TNN, TP53 and/or any combination thereof is indicative of decreased responsiveness of the cancer cell to the ERK inhibitor.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.